Literature DB >> 32682156

Design, synthesis and SARs of novel telomerase inhibitors based on BIBR1532.

Chao Liu1, Hua Zhou2, Xiao Bao Sheng3, Xin Hua Liu4, Fei Hu Chen5.   

Abstract

Telomerase has become one of the new popular targets for the development of anti-tumor drugs. Based on the structural characteristics of the BIBR1532 which has entered the stage of clinical research, six series total of 64 new compounds with diverse structural characteristics were designed and synthesized. The inhibitory activity against SGC-7901, MGC-803, SMMC-7721, A375 and GES cell lines and their telomerase inhibitory activity were tested. Among them, eight compounds showed good activity against cancer cells, among them compounds 56, 57 and 59 also showed low toxicity. Some of them showed excellent telomerase inhibitory activity with IC50 values ranging from 0.62 μM to 8.87 μM. Based on above, in depth structure-activity relationships were summarized, the compounds by replacing methyl group with cyanide and retaining amide moiety had good anti-tumor activity, moderate cytotoxicity, and better telomerase inhibitory activity. The results should be used for reference in BIBR1532-based structural optimization for further development of small molecule telomerase inhibitors.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BIBR1532; Design; Synthesis; TERT inhibitor; Telomerase inhibitor

Mesh:

Substances:

Year:  2020        PMID: 32682156     DOI: 10.1016/j.bioorg.2020.104077

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  1 in total

1.  New Genetic Bomb Trigger: Design, Synthesis, Molecular Dynamics Simulation, and Biological Evaluation of Novel BIBR1532-Related Analogs Targeting Telomerase against Non-Small Cell Lung Cancer.

Authors:  Haytham O Tawfik; Anwar A El-Hamaky; Eman A El-Bastawissy; Kirill A Shcherbakov; Alexander V Veselovsky; Yulia A Gladilina; Dmitry D Zhdanov; Mervat H El-Hamamsy
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.